Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Myelodysplastic Syndromes 3Small Cell Lung Carcinoma 2Melanoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Rectal Diseases 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Lung Neoplasms 1Kidney Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1

Interventions

Sunitinib 26Everolimus 20Bevacizumab 19aldesleukin 18Sorafenib 16Nivolumab 16Interleukin-2 14pembrolizumab 13Peripheral Blood Stem Cell Transplantation 13fludarabine phosphate 12Radiotherapy 12Interferon-alpha 12Cyclophosphamide 12Radiosurgery 11Filgrastim 11Blood Specimen Collection 11Ipilimumab 10Gemcitabine 10Axitinib 9Surveys and Questionnaires 7Gene Expression Profiling 7Cryosurgery 7temsirolimus 6pazopanib 6Surgical Procedures, Operative 6durvalumab 5cabozantinib 5atezolizumab 5Mycophenolic Acid 5Immunohistochemistry 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Kidney Neoplasms × guadecitabine × Clear all
NCT03308396 2022-02-17

Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

Big Ten Cancer Research Consortium

Phase 1/2 Active not recruiting
57 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡